CNBC July 30, 2024
Key Points
– The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term.
– That’s according to new data presented by Japanese drugmaker Eisai at a medical conference.
– The study results on Leqembi, which Eisai shares with Biogen, also found that the health of Alzheimer’s patients who take the therapy worsens after they stop treatment.
The breakthrough Alzheimer’s drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, according to new data released Tuesday by Japanese drugmaker Eisai.
The study results on Leqembi, which Eisai shares with Biogen, also found that...
Today's Sponsors
Today's Sponsor